241 related articles for article (PubMed ID: 26458285)
21. In vitro and in vivo anti-tumor effect of metformin as a novel therapeutic agent in human oral squamous cell carcinoma.
Luo Q; Hu D; Hu S; Yan M; Sun Z; Chen F
BMC Cancer; 2012 Nov; 12():517. PubMed ID: 23151022
[TBL] [Abstract][Full Text] [Related]
22. Combined cetuximab and genistein treatment shows additive anti-cancer effect on oral squamous cell carcinoma.
Park SJ; Kim MJ; Kim YK; Kim SM; Park JY; Myoung H
Cancer Lett; 2010 Jun; 292(1):54-63. PubMed ID: 19959278
[TBL] [Abstract][Full Text] [Related]
23. Enhanced antitumor effect of cisplatin in human NSCLC cells by tumor suppressor LKB1.
Ou W; Ye S; Yang W; Wang Y; Ma Q; Yu C; Shi H; Yuan Z; Zhong G; Ren J; Zhu W; Wei Y
Cancer Gene Ther; 2012 Jul; 19(7):489-98. PubMed ID: 22576699
[TBL] [Abstract][Full Text] [Related]
24. Bone invasion-targeted chemotherapy with a novel anionic platinum complex (3Pt) for oral squamous cell carcinoma.
Kasahara Y; Endo K; Ueno T; Ueno H; Moriyama-Kita M; Odani A; Yoshizaki T
Cancer Sci; 2019 Oct; 110(10):3288-3295. PubMed ID: 31348586
[TBL] [Abstract][Full Text] [Related]
25. STAT3 inhibitor WP1066 attenuates miRNA-21 to suppress human oral squamous cell carcinoma growth in vitro and in vivo.
Zhou X; Ren Y; Liu A; Han L; Zhang K; Li S; Li P; Li P; Kang C; Wang X; Zhang L
Oncol Rep; 2014 May; 31(5):2173-80. PubMed ID: 24676554
[TBL] [Abstract][Full Text] [Related]
26. Anticancer activity of pyrithione zinc in oral cancer cells identified in small molecule screens and xenograft model: Implications for oral cancer therapy.
Srivastava G; Matta A; Fu G; Somasundaram RT; Datti A; Walfish PG; Ralhan R
Mol Oncol; 2015 Oct; 9(8):1720-35. PubMed ID: 26115765
[TBL] [Abstract][Full Text] [Related]
27. Antitumor effect of poly lactic acid nanoparticles loaded with cisplatin and chloroquine on the oral squamous cell carcinoma.
Li Q; Liu X; Yan W; Chen Y
Aging (Albany NY); 2020 Dec; 13(2):2593-2603. PubMed ID: 33323546
[TBL] [Abstract][Full Text] [Related]
28. Oxysophocarpine Retards the Growth and Metastasis of Oral Squamous Cell Carcinoma by Targeting the Nrf2/HO-1 Axis.
Liu R; Peng J; Wang H; Li L; Wen X; Tan Y; Zhang L; Wan H; Chen F; Nie X
Cell Physiol Biochem; 2018; 49(5):1717-1733. PubMed ID: 30231242
[TBL] [Abstract][Full Text] [Related]
29. Retinoid interferon-induced mortality19 (GRIM19) inhibits proliferation and invasion in rheumatoid arthritis fibroblast-like synoviocytes.
Zhao D; Jiang Z; Wang Z; Gao J
Biomed Pharmacother; 2018 Feb; 98():719-725. PubMed ID: 29306209
[TBL] [Abstract][Full Text] [Related]
30. Therapeutic and preventive effects of an epidermal growth factor receptor inhibitor on oral squamous cell carcinoma.
Ge H; Liu H; Fu Z; Sun Z
J Int Med Res; 2012; 40(2):455-66. PubMed ID: 22613406
[TBL] [Abstract][Full Text] [Related]
31. The therapeutic potential of epigallocatechin‑3‑gallate against human oral squamous cell carcinoma through inhibition of cell proliferation and induction of apoptosis: In vitro and in vivo murine xenograft study.
Yoshimura H; Yoshida H; Matsuda S; Ryoke T; Ohta K; Ohmori M; Yamamoto S; Kiyoshima T; Kobayashi M; Sano K
Mol Med Rep; 2019 Aug; 20(2):1139-1148. PubMed ID: 31173211
[TBL] [Abstract][Full Text] [Related]
32. The role of NLRP3 inflammasome in 5-fluorouracil resistance of oral squamous cell carcinoma.
Feng X; Luo Q; Zhang H; Wang H; Chen W; Meng G; Chen F
J Exp Clin Cancer Res; 2017 Jun; 36(1):81. PubMed ID: 28637493
[TBL] [Abstract][Full Text] [Related]
33. Combined arsenic trioxide-cisplatin treatment enhances apoptosis in oral squamous cell carcinoma cells.
Nakaoka T; Ota A; Ono T; Karnan S; Konishi H; Furuhashi A; Ohmura Y; Yamada Y; Hosokawa Y; Kazaoka Y
Cell Oncol (Dordr); 2014 Apr; 37(2):119-29. PubMed ID: 24599717
[TBL] [Abstract][Full Text] [Related]
34. Silencing of GLUT-1 inhibits sensitization of oral cancer cells to cisplatin during hypoxia.
Shimanishi M; Ogi K; Sogabe Y; Kaneko T; Dehari H; Miyazaki A; Hiratsuka H
J Oral Pathol Med; 2013 May; 42(5):382-8. PubMed ID: 23227892
[TBL] [Abstract][Full Text] [Related]
35. Plasmid-based Stat3-specific siRNA and GRIM-19 inhibit the growth of thyroid cancer cells in vitro and in vivo.
Wang GM; Ren ZX; Wang PS; Su C; Zhang WX; Liu ZG; Zhang L; Zhao XJ; Chen G
Oncol Rep; 2014 Aug; 32(2):573-80. PubMed ID: 24899100
[TBL] [Abstract][Full Text] [Related]
36. WP1066 sensitizes oral squamous cell carcinoma cells to cisplatin by targeting STAT3/miR-21 axis.
Zhou X; Ren Y; Liu A; Jin R; Jiang Q; Huang Y; Kong L; Wang X; Zhang L
Sci Rep; 2014 Dec; 4():7461. PubMed ID: 25514838
[TBL] [Abstract][Full Text] [Related]
37. PNAS-4, a novel pro-apoptotic gene, can potentiate antineoplastic effects of cisplatin.
Yuan Z; Yan F; Wang YS; Liu HY; Gou LT; Zhao XY; Lai ST; Deng HX; Li J; Ding ZY; Xiong SQ; Kan B; Mao YQ; Chen LJ; Wei YQ; Zhao X
Cancer Chemother Pharmacol; 2009 Dec; 65(1):13-25. PubMed ID: 19387645
[TBL] [Abstract][Full Text] [Related]
38. Synergistic growth inhibition by sorafenib and cisplatin in human osteosarcoma cells.
Yang Q; Zhang S; Kang M; Dong R; Zhao J
Oncol Rep; 2015 May; 33(5):2537-44. PubMed ID: 25738402
[TBL] [Abstract][Full Text] [Related]
39. Grim-19 expressed by recombinant adenovirus for esophageal neoplasm target therapy.
Song J; Shi W; Wang W; Zhang Y; Zheng S
Mol Med Rep; 2018 May; 17(5):6667-6674. PubMed ID: 29488605
[TBL] [Abstract][Full Text] [Related]
40. p22phox confers resistance to cisplatin, by blocking its entry into the nucleus.
Hung CC; Chien CY; Chiang WF; Lin CS; Hour TC; Chen HR; Wang LF; Ko JY; Chang CH; Chen JY
Oncotarget; 2015 Feb; 6(6):4110-25. PubMed ID: 25686830
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
